Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, Siakavellas SI, Constantine-Cooke N, Jenkinson P, Su S, O'Hare C, Kirckpatrick L, Merchant LM, Noble C, Arnott ID, Jones GR, Lees CW. Derikx LAAP, et al. Among authors: siakavellas si. J Crohns Colitis. 2021 Dec 18;15(12):2011-2021. doi: 10.1093/ecco-jcc/jjab100. J Crohns Colitis. 2021. PMID: 34089587 Free PMC article.
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, Macdonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW. Plevris N, et al. J Gastroenterol Hepatol. 2021 Aug;36(8):2067-2075. doi: 10.1111/jgh.15390. Epub 2021 Mar 5. J Gastroenterol Hepatol. 2021. PMID: 33381875
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
Lyons M, Derikx LAAP, Fulforth J, McCall S, Plevris N, Jenkinson PW, Kirkwood K, Siakavellas S, Lucaciu L, Constantine-Cooke N, Arnott ID, Henderson P, Russell RK, Wilson DC, Lees CW, Jones GR. Lyons M, et al. Aliment Pharmacol Ther. 2022 Jul;56(1):67-76. doi: 10.1111/apt.16867. Epub 2022 Mar 17. Aliment Pharmacol Ther. 2022. PMID: 35301734 Free PMC article.
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones GR, Lees CW. Plevris N, et al. Among authors: siakavellas si. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1835-1844.e6. doi: 10.1016/j.cgh.2020.08.022. Epub 2020 Aug 13. Clin Gastroenterol Hepatol. 2021. PMID: 32798706
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA; PROTECT-ASUC Study Group. Sebastian S, et al. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):271-281. doi: 10.1016/S2468-1253(21)00016-9. Epub 2021 Feb 2. Lancet Gastroenterol Hepatol. 2021. PMID: 33545083 Free PMC article.
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S, Bhala N, Conley TE, Patel KV; PREPARE-IBD Collaborators; Lamb CA, Walker GJ, Kennedy NA, Sebastian S. Saifuddin A, et al. Aliment Pharmacol Ther. 2022 Nov;56(10):1460-1474. doi: 10.1111/apt.17223. Epub 2022 Oct 5. Aliment Pharmacol Ther. 2022. PMID: 36196569 Free PMC article.
Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Kostas A, et al. Among authors: siakavellas si. World J Gastroenterol. 2017 Nov 7;23(41):7387-7396. doi: 10.3748/wjg.v23.i41.7387. World J Gastroenterol. 2017. PMID: 29151692 Free PMC article.
41 results